Compare DOMH & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DOMH | COCH |
|---|---|---|
| Founded | 1967 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 51.3M |
| IPO Year | 2010 | 2021 |
| Metric | DOMH | COCH |
|---|---|---|
| Price | $0.85 | $6.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 159.5K | 30.3K |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | ★ 121.20% | N/A |
| EPS Growth | ★ 34.03 | 17.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | $241,000.00 |
| Revenue This Year | N/A | $24.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | 7.11 |
| 52 Week Low | $0.70 | $4.72 |
| 52 Week High | $5.10 | $47.70 |
| Indicator | DOMH | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 18.83 | 17.62 |
| Support Level | N/A | $4.72 |
| Resistance Level | $3.33 | $7.46 |
| Average True Range (ATR) | 0.15 | 0.49 |
| MACD | -0.08 | 1.03 |
| Stochastic Oscillator | 8.24 | 42.28 |
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.